Zymeworks(ZYME) - 2024 Q2 - Quarterly Results

Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results • Reported $395.9 million in cash resources as of June 30, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027 • Priority Review of the Biologics License Application (BLA) granted for zanidatamab as second-line (2L) treatment for HER2-positive biliary tract cancers (BTC) in the United States with target action date of November 29, 2024 • The European ...